The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a huge mover today! About 1.35M shares traded hands. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 40.71% since March 15, 2016 and is downtrending. It has underperformed by 46.20% the S&P500.
The move comes after 7 months positive chart setup for the $3.41 billion company. It was reported on Oct, 18 by Barchart.com. We have $57.23 PT which if reached, will make NASDAQ:ALNY worth $1.67 billion more.
Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on November, 14. They expect $-1.20 earnings per share, down 31.87% or $0.29 from last year’s $-0.91 per share. After $-1.05 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage
Out of 14 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 57% are positive. Alnylam Pharmaceuticals has been the topic of 29 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating given on Friday, March 11 by JP Morgan. The firm earned “Overweight” rating on Tuesday, August 2 by Morgan Stanley. The rating was maintained by Leerink Swann on Tuesday, February 16 with “Outperform”. The stock has “Neutral” rating given by JP Morgan on Thursday, October 6. The firm has “Neutral” rating given on Thursday, October 6 by Goldman Sachs. The company was downgraded on Thursday, October 6 by Leerink Swann. FBR Capital maintained the shares of ALNY in a report on Thursday, October 6 with “Outperform” rating. Chardan Capital Markets maintained it with “Buy” rating and $77 target price in Thursday, October 6 report. The firm has “Buy” rating given on Thursday, October 6 by Jefferies. The firm has “Outperform” rating by Credit Suisse given on Thursday, October 6.
According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”
Insitutional Activity: The institutional sentiment decreased to 1.27 in Q2 2016. Its down 0.21, from 1.48 in 2016Q1. The ratio fall, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Rtw Investments Ltd holds 15.78% or 832,549 shares in its portfolio. The Netherlands-based Apg Asset Management Nv has invested 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Jp Marvel Investment Advisors Limited Liability holds 52,294 shares or 1.02% of its portfolio. Winfield Assocs Incorporated accumulated 20 shares or 0% of the stock. Glenmede Tru Na, a Pennsylvania-based fund reported 500 shares. Moreover, Profund Advisors Ltd Liability Corp has 0.11% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 40,104 shares. Parametric Portfolio Assocs, a Washington-based fund reported 38,077 shares. Da Davidson, a Montana-based fund reported 115 shares. Moreover, Bluemountain Management Ltd has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 9,608 shares. Kcg Holdings holds 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 14,377 shares. Blackrock Advisors Llc last reported 0.02% of its portfolio in the stock. Wells Fargo And Mn holds 698,398 shares or 0.02% of its portfolio. Oregon Employees Retirement Fund has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Amalgamated National Bank & Trust accumulated 11,565 shares or 0.05% of the stock. The Australia-based Westpac Bk Corporation has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Insider Transactions: Since April 19, 2016, the stock had 1 insider purchase, and 1 sale for $918,262 net activity. $1.95M worth of shares were sold by MARAGANORE JOHN on Tuesday, July 19. On Thursday, October 13 the insider PYOTT DAVID E I bought $1.03 million.
More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.” on October 10, 2016, also Fool.com with their article: “What’s Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?” published on October 07, 2016, Fool.com published: “Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc.” on September 24, 2016. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Finance.Yahoo.com and their article: “Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Operating …” published on September 21, 2016 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” with publication date: October 06, 2016.
ALNY Company Profile
Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.